ASX - By Stock
|
CHM |
Re:
Ann: CHM CDH17 Phase 1/2 clinical trial approved for initiation
|
|
pinch2020
|
18 |
6.0K |
5 |
29/05/24 |
29/05/24 |
ASX - By Stock
|
18
|
6.0K
|
5
|
|
ASX - By Stock
|
CHM |
Re:
Ann: CHM CORE-NK vactosertib Phase 1b study re-opens enrolment
|
|
pinch2020
|
17 |
3.9K |
3 |
22/05/24 |
22/05/24 |
ASX - By Stock
|
17
|
3.9K
|
3
|
|
ASX - By Stock
|
CHM |
Re:
Ann: CHM CDH17 Phase 1/2 clinical trial approved for initiation
|
|
pinch2020
|
18 |
6.0K |
13 |
20/05/24 |
20/05/24 |
ASX - By Stock
|
18
|
6.0K
|
13
|
|
ASX - By Stock
|
CHM |
Re:
Ann: FDA clearance of IND for CHM 2101
|
|
pinch2020
|
75 |
22K |
3 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
75
|
22K
|
3
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Notice of Extraordinary General Meeting/Proxy Form
|
|
pinch2020
|
149 |
36K |
1 |
14/05/24 |
14/05/24 |
ASX - By Stock
|
149
|
36K
|
1
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Notice of Extraordinary General Meeting/Proxy Form
|
|
pinch2020
|
149 |
36K |
8 |
14/05/24 |
14/05/24 |
ASX - By Stock
|
149
|
36K
|
8
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Notice of Extraordinary General Meeting/Proxy Form
|
|
pinch2020
|
149 |
36K |
6 |
14/05/24 |
14/05/24 |
ASX - By Stock
|
149
|
36K
|
6
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Notice of Extraordinary General Meeting/Proxy Form
|
|
pinch2020
|
149 |
36K |
11 |
13/05/24 |
13/05/24 |
ASX - By Stock
|
149
|
36K
|
11
|
|
ASX - By Stock
|
SMN |
Re:
Ann: An Update from the Executive Chairman
|
|
pinch2020
|
174 |
50K |
3 |
09/05/24 |
09/05/24 |
ASX - By Stock
|
174
|
50K
|
3
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Dr Rebecca McQualter appointed COO
|
|
pinch2020
|
14 |
5.4K |
5 |
08/05/24 |
08/05/24 |
ASX - By Stock
|
14
|
5.4K
|
5
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
pinch2020
|
694 |
280K |
3 |
08/05/24 |
08/05/24 |
ASX - By Stock
|
694
|
280K
|
3
|
|
ASX - By Stock
|
CHM |
Re:
Ann: 1st patient treated in ADVENT-AML Phase 1b clinical trial
|
|
pinch2020
|
43 |
18K |
8 |
07/05/24 |
07/05/24 |
ASX - By Stock
|
43
|
18K
|
8
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
pinch2020
|
694 |
280K |
15 |
03/05/24 |
03/05/24 |
ASX - By Stock
|
694
|
280K
|
15
|
|
ASX - By Stock
|
CHM |
Re:
New email reg. JC
|
|
pinch2020
|
12 |
3.5K |
8 |
01/05/24 |
01/05/24 |
ASX - By Stock
|
12
|
3.5K
|
8
|
|
ASX - By Stock
|
SMN |
Re:
Ann: An Update from the Executive Chairman
|
|
pinch2020
|
174 |
50K |
15 |
01/05/24 |
01/05/24 |
ASX - By Stock
|
174
|
50K
|
15
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
pinch2020
|
694 |
280K |
5 |
30/04/24 |
30/04/24 |
ASX - By Stock
|
694
|
280K
|
5
|
|
ASX - By Stock
|
SMN |
Re:
Ann: An Update from the Executive Chairman
|
|
pinch2020
|
174 |
50K |
6 |
29/04/24 |
29/04/24 |
ASX - By Stock
|
174
|
50K
|
6
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
pinch2020
|
694 |
280K |
12 |
28/04/24 |
28/04/24 |
ASX - By Stock
|
694
|
280K
|
12
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
pinch2020
|
694 |
280K |
16 |
28/04/24 |
28/04/24 |
ASX - By Stock
|
694
|
280K
|
16
|
|
ASX - By Stock
|
WBT |
Re:
Weebit - 2024 and beyond
|
|
pinch2020
|
1.3K |
529K |
15 |
24/04/24 |
24/04/24 |
ASX - By Stock
|
1.3K
|
529K
|
15
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
pinch2020
|
694 |
280K |
3 |
22/04/24 |
22/04/24 |
ASX - By Stock
|
694
|
280K
|
3
|
|
ASX - By Stock
|
CHM |
Re:
Charting Only
|
|
pinch2020
|
428 |
150K |
2 |
19/04/24 |
19/04/24 |
ASX - By Stock
|
428
|
150K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
pinch2020
|
694 |
280K |
10 |
19/04/24 |
19/04/24 |
ASX - By Stock
|
694
|
280K
|
10
|
|
ASX - By Stock
|
WBT |
Re:
WBT Industry Related Off Topic.
|
|
pinch2020
|
1.2K |
554K |
20 |
12/04/24 |
12/04/24 |
ASX - By Stock
|
1.2K
|
554K
|
20
|
|
ASX - By Stock
|
CHM |
Re:
Charting Only
|
|
pinch2020
|
428 |
150K |
10 |
12/04/24 |
12/04/24 |
ASX - By Stock
|
428
|
150K
|
10
|
|
ASX - By Stock
|
WBT |
Re:
Weebit - 2024 and beyond
|
|
pinch2020
|
1.3K |
529K |
22 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
1.3K
|
529K
|
22
|
|
ASX - By Stock
|
CHM |
Re:
Ann: US patent allowed for CHM 0201 (CORE-NK) technology
|
|
pinch2020
|
15 |
5.6K |
4 |
07/04/24 |
07/04/24 |
ASX - By Stock
|
15
|
5.6K
|
4
|
|
ASX - By Stock
|
WBT |
Re:
Weebit - 2024 and beyond
|
|
pinch2020
|
1.3K |
529K |
0 |
05/04/24 |
05/04/24 |
ASX - By Stock
|
1.3K
|
529K
|
0
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
pinch2020
|
694 |
280K |
6 |
05/04/24 |
05/04/24 |
ASX - By Stock
|
694
|
280K
|
6
|
|
ASX - By Stock
|
CHM |
Re:
Ann: 1st patient treated in ADVENT-AML Phase 1b clinical trial
|
|
pinch2020
|
43 |
18K |
10 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
43
|
18K
|
10
|
|
ASX - By Stock
|
WBT |
Re:
WBT Industry Related Off Topic.
|
|
pinch2020
|
1.2K |
554K |
6 |
01/04/24 |
01/04/24 |
ASX - By Stock
|
1.2K
|
554K
|
6
|
|
ASX - By Stock
|
WBT |
Re:
WBT Industry Related Off Topic.
|
|
pinch2020
|
1.2K |
554K |
7 |
28/03/24 |
28/03/24 |
ASX - By Stock
|
1.2K
|
554K
|
7
|
|
ASX - By Stock
|
CHM |
Re:
Ann: 1st patient treated in ADVENT-AML Phase 1b clinical trial
|
|
pinch2020
|
43 |
18K |
5 |
23/03/24 |
23/03/24 |
ASX - By Stock
|
43
|
18K
|
5
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Chimeric to present at NWR Virtual Healthcare Conference
|
|
pinch2020
|
22 |
7.4K |
2 |
23/03/24 |
23/03/24 |
ASX - By Stock
|
22
|
7.4K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Clinical milestones for 2024 & 2023 successes highlighted
|
|
pinch2020
|
26 |
9.4K |
2 |
20/03/24 |
20/03/24 |
ASX - By Stock
|
26
|
9.4K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Clinical milestones for 2024 & 2023 successes highlighted
|
|
pinch2020
|
26 |
9.4K |
6 |
20/03/24 |
20/03/24 |
ASX - By Stock
|
26
|
9.4K
|
6
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Clinical milestones for 2024 & 2023 successes highlighted
|
|
pinch2020
|
26 |
9.4K |
3 |
20/03/24 |
20/03/24 |
ASX - By Stock
|
26
|
9.4K
|
3
|
|
ASX - By Stock
|
WBT |
Re:
Ann: Weebit Nano Investor Presentation
|
|
pinch2020
|
184 |
71K |
25 |
19/03/24 |
19/03/24 |
ASX - By Stock
|
184
|
71K
|
25
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Clinical milestones for 2024 & 2023 successes highlighted
|
|
pinch2020
|
26 |
9.4K |
8 |
14/03/24 |
14/03/24 |
ASX - By Stock
|
26
|
9.4K
|
8
|
|
ASX - By Stock
|
CHM |
Re:
Ann: New data for Phase 1A CLTX CAR T brain cancer clinical trial
|
|
pinch2020
|
75 |
26K |
2 |
14/03/24 |
14/03/24 |
ASX - By Stock
|
75
|
26K
|
2
|
|
ASX - By Stock
|
WBT |
Re:
Weebit - 2024 and beyond
|
|
pinch2020
|
1.3K |
529K |
4 |
11/03/24 |
11/03/24 |
ASX - By Stock
|
1.3K
|
529K
|
4
|
|
ASX - By Stock
|
CHM |
Re:
Ann: 1st patient treated in ADVENT-AML Phase 1b clinical trial
|
|
pinch2020
|
43 |
18K |
4 |
09/03/24 |
09/03/24 |
ASX - By Stock
|
43
|
18K
|
4
|
|
ASX - By Stock
|
CHM |
Re:
Ann: 1st patient treated in ADVENT-AML Phase 1b clinical trial
|
|
pinch2020
|
43 |
18K |
0 |
08/03/24 |
08/03/24 |
ASX - By Stock
|
43
|
18K
|
0
|
|
ASX - By Stock
|
CHM |
Re:
Ann: New data for Phase 1A CLTX CAR T brain cancer clinical trial
|
|
pinch2020
|
75 |
26K |
4 |
08/03/24 |
08/03/24 |
ASX - By Stock
|
75
|
26K
|
4
|
|
ASX - By Stock
|
CHM |
Re:
Ann: 1st patient treated in ADVENT-AML Phase 1b clinical trial
|
|
pinch2020
|
43 |
18K |
6 |
08/03/24 |
08/03/24 |
ASX - By Stock
|
43
|
18K
|
6
|
|
ASX - By Stock
|
CHM |
Re:
Ann: 1st patient treated in ADVENT-AML Phase 1b clinical trial
|
|
pinch2020
|
43 |
18K |
3 |
06/03/24 |
06/03/24 |
ASX - By Stock
|
43
|
18K
|
3
|
|
ASX - By Stock
|
SMN |
Re:
Ann: Structural Monitoring Systems Investor Webinar
|
|
pinch2020
|
121 |
33K |
4 |
06/03/24 |
06/03/24 |
ASX - By Stock
|
121
|
33K
|
4
|
|
ASX - By Stock
|
CHM |
Re:
Charting Only
|
|
pinch2020
|
428 |
150K |
7 |
05/03/24 |
05/03/24 |
ASX - By Stock
|
428
|
150K
|
7
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Chimeric to present at ********* Hidden Gems webinar
|
|
pinch2020
|
17 |
5.5K |
5 |
05/03/24 |
05/03/24 |
ASX - By Stock
|
17
|
5.5K
|
5
|
|
ASX - By Stock
|
WBT |
Re:
Weebit - 2024 and beyond
|
|
pinch2020
|
1.3K |
529K |
2 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
1.3K
|
529K
|
2
|
|